0001752724-24-010258.txt : 20240124
0001752724-24-010258.hdr.sgml : 20240124
20240124132254
ACCESSION NUMBER: 0001752724-24-010258
CONFORMED SUBMISSION TYPE: NPORT-P
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20231130
FILED AS OF DATE: 20240124
DATE AS OF CHANGE: 20240124
PERIOD START: 20240229
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BNY Mellon ETF Trust
CENTRAL INDEX KEY: 0001493580
ORGANIZATION NAME:
IRS NUMBER: 000000000
STATE OF INCORPORATION: MA
FILING VALUES:
FORM TYPE: NPORT-P
SEC ACT: 1940 Act
SEC FILE NUMBER: 811-23477
FILM NUMBER: 24555541
BUSINESS ADDRESS:
STREET 1: 240 GREENWICH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10286
BUSINESS PHONE: 212-922-6400
MAIL ADDRESS:
STREET 1: 240 GREENWICH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10286
FORMER COMPANY:
FORMER CONFORMED NAME: Dreyfus ETF Trust
DATE OF NAME CHANGE: 20100607
0001493580
S000080183
BNY Mellon Innovators ETF
C000241887
BNY Mellon Innovators ETF
BKIV
NPORT-P
1
primary_doc.xml
NPORT-P
false
0001493580
XXXXXXXX
S000080183
C000241887
BNY Mellon ETF Trust
811-23477
0001493580
549300E2C8EQYJ7B0H81
240 Greenwich Street
New York
10286
212-922-6400
BNY Mellon Innovators ETF
S000080183
5493008VNZDSC0PFVK32
2024-02-29
2023-11-30
N
10283233.29
4016.17
10279217.12
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
N
Outset Medical Inc
N/A
Outset Medical Inc
690145107
7531.00000000
NS
USD
39462.44000000
0.383905112026
Long
EC
CORP
US
N
1
N
N
N
Denali Therapeutics Inc
549300ZTQ2HO18L3Q830
Denali Therapeutics Inc
24823R105
5092.00000000
NS
USD
94303.84000000
0.917422396074
Long
EC
CORP
US
N
1
N
N
N
iRhythm Technologies Inc
549300FJI72RJGDQS384
iRhythm Technologies Inc
450056106
1372.00000000
NS
USD
117004.16000000
1.138259447524
Long
EC
CORP
US
N
1
N
N
N
Dynatrace Inc
N/A
Dynatrace Inc
268150109
4290.00000000
NS
USD
229729.50000000
2.234892962354
Long
EC
CORP
US
N
1
N
N
N
DoubleVerify Holdings Inc
N/A
DoubleVerify Holdings Inc
25862V105
5288.00000000
NS
USD
175561.60000000
1.707927733702
Long
EC
CORP
US
N
1
N
N
N
Shopify Inc
549300HGQ43STJLLP808
Shopify Inc
82509L107
3323.00000000
NS
USD
241980.86000000
2.354078692716
Long
EC
CORP
CA
N
1
N
N
N
Vital Farms Inc
549300S6NYY7ER3XOT61
Vital Farms Inc
92847W103
6799.00000000
NS
USD
90562.68000000
0.881027017357
Long
EC
CORP
US
N
1
N
N
N
10X Genomics Inc
5493003Z6741WNLG7H43
10X Genomics Inc
88025U109
2882.00000000
NS
USD
125424.64000000
1.220176970053
Long
EC
CORP
US
N
1
N
N
N
Dreyfus Institutional Preferred Government Money Market Fund
549300RBWL04JG8SIX57
Dreyfus Institutional Preferred Government Money Market Fund
000000000
53346.27000000
NS
USD
53346.27000000
0.518972110202
Long
STIV
RF
US
N
1
N
N
N
Illumina Inc
SQ95QG8SR5Q56LSNF682
Illumina Inc
452327109
1534.00000000
NS
USD
156391.30000000
1.521432013491
Long
EC
CORP
US
N
1
N
N
N
MongoDB Inc
549300TPTG69WKWE1Z37
MongoDB Inc
60937P106
536.00000000
NS
USD
222836.64000000
2.167836688325
Long
EC
CORP
US
N
1
N
N
N
Ares Management Corp
529900JUV61FH7B8VW38
Ares Management Corp
03990B101
3034.00000000
NS
USD
340566.50000000
3.313156012021
Long
EC
CORP
US
N
1
N
N
N
BioMarin Pharmaceutical Inc
NSLL8ITTRR0J5HEMR848
BioMarin Pharmaceutical Inc
09061G101
2736.00000000
NS
USD
249194.88000000
2.424259329196
Long
EC
CORP
US
N
1
N
N
N
Crinetics Pharmaceuticals Inc
549300Q1CNFXK5P31D28
Crinetics Pharmaceuticals Inc
22663K107
4507.00000000
NS
USD
143277.53000000
1.393856441861
Long
EC
CORP
US
N
1
N
N
N
Liberty Media Corp-Liberty For
N/A
Liberty Media Corp-Liberty Formula One
531229755
2727.00000000
NS
USD
173600.82000000
1.688852545610
Long
EC
CORP
US
N
1
N
N
N
CoStar Group Inc
N/A
CoStar Group Inc
22160N109
5112.00000000
NS
USD
424500.48000000
4.129696600863
Long
EC
CORP
US
N
1
N
N
N
Netflix Inc
549300Y7VHGU0I7CE873
Netflix Inc
64110L106
742.00000000
NS
USD
351685.74000000
3.421328063162
Long
EC
CORP
US
N
1
N
N
N
Cactus Inc
549300J3T8C9F8QFKV08
Cactus Inc
127203107
7721.00000000
NS
USD
328065.29000000
3.191539649081
Long
EC
CORP
US
N
1
N
N
N
Twilio Inc
5493004W8TRGD63APX93
Twilio Inc
90138F102
5256.00000000
NS
USD
339958.08000000
3.307237078770
Long
EC
CORP
US
N
1
N
N
N
NVIDIA Corp
549300S4KLFTLO7GSQ80
NVIDIA Corp
67066G104
1673.00000000
NS
USD
782462.10000000
7.612078729980
Long
EC
CORP
US
N
1
N
N
N
Celsius Holdings Inc
N/A
Celsius Holdings Inc
15118V207
1761.00000000
NS
USD
87187.11000000
0.848188232451
Long
EC
CORP
US
N
1
N
N
N
Freshpet Inc
549300S4ZK8ZQ6HNPN59
Freshpet Inc
358039105
3150.00000000
NS
USD
223492.50000000
2.174217135322
Long
EC
CORP
US
N
1
N
N
N
Peloton Interactive Inc
5493002YS021166W0339
Peloton Interactive Inc
70614W100
28280.00000000
NS
USD
160064.80000000
1.557169170875
Long
EC
CORP
US
N
1
N
N
N
Ascendis Pharma A/S
549300B66JN3W3J8GH73
Ascendis Pharma A/S
04351P101
2229.00000000
NS
USD
223858.47000000
2.177777425913
Long
EC
CORP
DK
N
1
N
N
N
DraftKings Inc
N/A
DraftKings Inc
26142V105
4416.00000000
NS
USD
168867.84000000
1.642808377609
Long
EC
CORP
US
N
1
N
N
N
Snowflake Inc
254900CJNSY1K7T53Z16
Snowflake Inc
833445109
1906.00000000
NS
USD
357718.08000000
3.480012882537
Long
EC
CORP
US
N
1
N
N
N
Align Technology Inc
549300N5YSE0U3LCP840
Align Technology Inc
016255101
866.00000000
NS
USD
185150.80000000
1.801214993695
Long
EC
CORP
US
N
1
N
N
N
Privia Health Group Inc
N/A
Privia Health Group Inc
74276R102
5953.00000000
NS
USD
122988.98000000
1.196481974884
Long
EC
CORP
US
N
1
N
N
N
Repligen Corp
54930006QJ0T5AUO1E71
Repligen Corp
759916109
1319.00000000
NS
USD
207412.75000000
2.017787420760
Long
EC
CORP
US
N
1
N
N
N
Prothena Corp PLC
5299009ZXQ8NIIJ8OL30
Prothena Corp PLC
000000000
1993.00000000
NS
USD
64931.94000000
0.631681763717
Long
EC
CORP
IE
N
1
N
N
N
Garmin Ltd
2549001E0HIPIJQ0W046
Garmin Ltd
000000000
981.00000000
NS
USD
119917.44000000
1.166600905497
Long
EC
CORP
CH
N
1
N
N
N
Keros Therapeutics Inc
N/A
Keros Therapeutics Inc
492327101
2185.00000000
NS
USD
66292.90000000
0.644921682518
Long
EC
CORP
US
N
1
N
N
N
Trade Desk Inc/The
549300GXPD31VT3E0P46
Trade Desk Inc/The
88339J105
3052.00000000
NS
USD
215043.92000000
2.092026245671
Long
EC
CORP
US
N
1
N
N
N
TransMedics Group Inc
549300060GVOSMWARH50
TransMedics Group Inc
89377M109
2484.00000000
NS
USD
187989.12000000
1.828827213253
Long
EC
CORP
US
N
1
N
N
N
Chewy Inc
254900NPQSTG9I422879
Chewy Inc
16679L109
2969.00000000
NS
USD
51719.98000000
0.503150963699
Long
EC
CORP
US
N
1
N
N
N
Alphabet Inc
5493006MHB84DD0ZWV18
Alphabet Inc
02079K107
4155.00000000
NS
USD
556437.60000000
5.413229368580
Long
EC
CORP
US
N
1
N
N
N
Intuitive Surgical Inc
54930052SRG011710797
Intuitive Surgical Inc
46120E602
655.00000000
NS
USD
203600.20000000
1.980697533899
Long
EC
CORP
US
N
1
N
N
N
Xenon Pharmaceuticals Inc
549300XV44Q9Z1MIPQ03
Xenon Pharmaceuticals Inc
98420N105
1723.00000000
NS
USD
63027.34000000
0.613153115302
Long
EC
CORP
CA
N
1
N
N
N
Sarepta Therapeutics Inc
549300IKDPIED8J8IG21
Sarepta Therapeutics Inc
803607100
1577.00000000
NS
USD
128178.56000000
1.246968115408
Long
EC
CORP
US
N
1
N
N
N
Inspire Medical Systems Inc
549300XQQCQ7HCJKTW25
Inspire Medical Systems Inc
457730109
899.00000000
NS
USD
130633.69000000
1.270852521889
Long
EC
CORP
US
N
1
N
N
N
Pacific Biosciences of Califor
529900F1BWRE1M0KZN89
Pacific Biosciences of California Inc
69404D108
11878.00000000
NS
USD
100725.44000000
0.979894079715
Long
EC
CORP
US
N
1
N
N
N
Albemarle Corp
HDBLS2Q6GV1LSKQPBS54
Albemarle Corp
012653101
971.00000000
NS
USD
117753.17000000
1.145546091938
Long
EC
CORP
US
N
1
N
N
N
Block Inc
549300OHIIUWSTIZME52
Block Inc
852234103
4013.00000000
NS
USD
254544.59000000
2.476303273181
Long
EC
CORP
US
N
1
N
N
N
Alnylam Pharmaceuticals Inc
529900S3ZI14OWRJII50
Alnylam Pharmaceuticals Inc
02043Q107
1045.00000000
NS
USD
175821.25000000
1.710453704279
Long
EC
CORP
US
N
1
N
N
N
Airbnb Inc
549300HMUDNO0RY56D37
Airbnb Inc
009066101
1398.00000000
NS
USD
176623.32000000
1.718256535863
Long
EC
CORP
US
N
1
N
N
N
Dexcom Inc
549300YSK3QDSFR5EU59
Dexcom Inc
252131107
3080.00000000
NS
USD
355801.60000000
3.461368661118
Long
EC
CORP
US
N
1
N
N
N
Lululemon Athletica Inc
549300D9GZ4BMLDW5T40
Lululemon Athletica Inc
550021109
678.00000000
NS
USD
302930.40000000
2.947018206382
Long
EC
CORP
CA
N
1
N
N
N
Insmed Inc
529900Q55QAG41CCAC11
Insmed Inc
457669307
10879.00000000
NS
USD
272192.58000000
2.647989402523
Long
EC
CORP
US
N
1
N
N
N
Twist Bioscience Corp
549300T23BL59LCOH584
Twist Bioscience Corp
90184D100
7778.00000000
NS
USD
187060.90000000
1.819797148131
Long
EC
CORP
US
N
1
N
N
N
Cytokinetics Inc
549300BE5DY1HW7IHA64
Cytokinetics Inc
23282W605
4005.00000000
NS
USD
134087.40000000
1.304451481417
Long
EC
CORP
US
N
1
N
N
N
2024-01-17
BNY Mellon ETF Trust
James Windels
James Windels
Treasurer
XXXX
NPORT-EX
2
647973BNYM113023.htm
STATEMENT
OF
INVESTMENTS
November
30,
2023
(Unaudited)
Description
Shares
Value
($)
Common
Stocks
–
99.5%
Consumer
Discretionary
Distribution
&
Retail
–
0.5%
Chewy,
Inc.,
Class
A
(a)
2,969
51,720
Consumer
Durables
&
Apparel
–
5.7%
Garmin
Ltd.
981
119,918
Lululemon
Athletica,
Inc.
(a)
678
302,930
Peloton
Interactive,
Inc.,
Class
A
(a)
28,280
160,065
582,913
Consumer
Services
–
3.4%
Airbnb,
Inc.,
Class
A
(a)
1,398
176,623
DraftKings,
Inc.,
Class
A
(a)
4,416
168,868
345,491
Energy
–
3.2%
Cactus,
Inc.,
Class
A
7,721
328,065
Financial
Services
–
5.8%
Ares
Management
Corp.,
Class
A
3,034
340,566
Block,
Inc.
(a)
4,013
254,545
595,111
Food,
Beverage
&
Tobacco
–
3.9%
Celsius
Holdings,
Inc.
(a)
1,761
87,187
Freshpet,
Inc.
(a)
3,150
223,492
Vital
Farms,
Inc.
(a)
6,799
90,563
401,242
Health
Care
Equipment
&
Services
–
13.1%
Align
Technology,
Inc.
(a)
866
185,151
DexCom,
Inc.
(a)
3,080
355,802
Inspire
Medical
Systems,
Inc.
(a)
899
130,634
Intuitive
Surgical,
Inc.
(a)
655
203,600
iRhythm
Technologies,
Inc.
(a)
1,372
117,004
Outset
Medical,
Inc.
(a)
7,531
39,462
Privia
Health
Group,
Inc.
(a)
5,953
122,989
TransMedics
Group,
Inc.
(a)
2,484
187,989
1,342,631
Materials
–
1.1%
Albemarle
Corp.
971
117,753
Media
&
Entertainment
–
12.6%
Alphabet,
Inc.,
Class
C
(a)
4,155
556,437
Liberty
Media
Corp.-Liberty
Formula
One,
Class
C
(a)
2,727
173,601
Netflix,
Inc.
(a)
742
351,686
Trade
Desk,
Inc.
(The),
Class
A
(a)
3,052
215,044
1,296,768
Pharmaceuticals,
Biotechnology
&
Life
Sciences
–
23.3%
10X
Genomics,
Inc.,
Class
A
(a)
2,882
125,425
Alnylam
Pharmaceuticals,
Inc.
(a)
1,045
175,821
STATEMENT
OF
INVESTMENTS
(continued)
See
Notes
to
Statement
of
Investments
Description
Shares
Value
($)
Common
Stocks
–
99.5%
(continued)
Pharmaceuticals,
Biotechnology
&
Life
Sciences
–
23.3%
(continued)
Ascendis
Pharma
A/S,
ADR
(a)
2,229
223,858
BioMarin
Pharmaceutical,
Inc.
(a)
2,736
249,195
Crinetics
Pharmaceuticals,
Inc.
(a)
4,507
143,278
Cytokinetics,
Inc.
(a)
4,005
134,087
Denali
Therapeutics,
Inc.
(a)
5,092
94,304
Illumina,
Inc.
(a)
1,534
156,391
Insmed,
Inc.
(a)
10,879
272,193
Keros
Therapeutics,
Inc.
(a)
2,185
66,293
Pacific
Biosciences
of
California,
Inc.
(a)
11,878
100,725
Prothena
Corp.
PLC
(a)
1,993
64,932
Repligen
Corp.
(a)
1,319
207,413
Sarepta
Therapeutics,
Inc.
(a)
1,577
128,179
Twist
Bioscience
Corp.
(a)
7,778
187,061
Xenon
Pharmaceuticals,
Inc.
(a)
1,723
63,027
2,392,182
Real
Estate
Management
&
Development
–
4.1%
CoStar
Group,
Inc.
(a)
5,112
424,501
Semiconductors
&
Semiconductor
Equipment
–
7.6%
NVIDIA
Corp.
1,673
782,462
Software
&
Services
–
15.2%
DoubleVerify
Holdings,
Inc.
(a)
5,288
175,562
Dynatrace,
Inc.
(a)
4,290
229,729
MongoDB,
Inc.
(a)
536
222,837
Shopify,
Inc.,
Class
A
(a)
3,323
241,981
Snowflake,
Inc.,
Class
A
(a)
1,906
357,718
Twilio,
Inc.,
Class
A
(a)
5,256
339,958
1,567,785
Total
Common
Stocks
(cost
$9,909,831)
10,228,624
Investment
Companies
–
0.5%
Registered
Investment
Companies
–
0.5%
Dreyfus
Institutional
Preferred
Government
Money
Market
Fund,
Institutional
Shares,
5.32%
(b)(c)
(cost
$53,346)
53,346
53,346
Total
Investments
(cost
$9,963,177)
100.0%
10,281,970
Liabilities,
Less
Cash
and
Receivables
0.0%
(2,753)
Net
Assets
100.0%
10,279,217
ADR—American
Depositary
Receipt
(a)
Non-income
producing
security.
(b)
Investment
in
affiliated
issuer.
The
investment
objective
of
this
investment
company
is
publicly
available
and
can
be
found
within
the
investment
company’s
prospectus.
(c)
The
rate
shown
is
the
1-day
yield
as
of
November
30,
2023.
NOTES
TO
STATEMENT
OF
INVESTMENTS
(Unaudited)
The
Financial
Accounting
Standards
Board
(“FASB”)
Accounting
Standards
Codification
(“ASC”)
is
the
exclusive
reference
of
authoritative
U.S.
generally
accepted
accounting
principles
(“GAAP”)
recognized
by
the
FASB
to
be
applied
by
nongovernmental
entities.
Rules
and
interpretive
releases
of
the
Securities
and
Exchange
Commission
(“SEC”)
under
authority
of
federal
laws
are
also
sources
of
authoritative
GAAP
for
SEC
registrants. BNY
Mellon
Innovators
ETF (the
“fund”)
is an
investment
company
and
applies
the
accounting
and
reporting
guidance
of
the
FASB
ASC
Topic
946
Financial
Services-Investment
Companies. The
fund’s
financial
statements
are
prepared
in
accordance
with
GAAP,
which
may
require
the
use
of
management
estimates
and
assumptions.
Actual
results
could
differ
from
those
estimates.
(a)
Portfolio
valuation:
The
fair
value
of
a
financial
instrument
is
the
amount
that
would
be
received
to
sell
an
asset
or
paid
to
transfer
a
liability
in
an
orderly
transaction
between
market
participants
at
the
measurement
date
(i.e.,
the
exit
price).
GAAP
establishes
a
fair
value
hierarchy
that
prioritizes
the
inputs
of
valuation
techniques
used
to
measure
fair
value.
This
hierarchy
gives
the
highest
priority
to
unadjusted
quoted
prices
in
active
markets
for
identical
assets
or
liabilities
(Level
1
measurements)
and
the
lowest
priority
to
unobservable
inputs
(Level
3
measurements).
Additionally,
GAAP
provides
guidance
on
determining
whether
the
volume
and
activity
in
a
market
has
decreased
significantly
and
whether
such
a
decrease
in
activity
results
in
transactions
that
are
not
orderly.
GAAP
requires
enhanced
disclosures
around
valuation
inputs
and
techniques
used
during
annual
and
interim
periods.
Various
inputs
are
used
in
determining
the
value
of
the
fund’s
investments
relating
to
fair
value
measurements.
These
inputs
are
summarized
in
the
three
broad
levels
listed
below:
Level
1
—
unadjusted
quoted
prices
in
active
markets
for
identical
investments.
Level
2
—
other
significant
observable
inputs
(including
quoted
prices
for
similar
investments,
interest
rates,
prepayment
speeds,
credit
risk,
etc.).
Level
3
—
significant
unobservable
inputs
(including
the
fund’s
own
assumptions
in
determining
the
fair
value
of
investments).
The
inputs
or
methodology
used
for
valuing
securities
are
not
necessarily
an
indication
of
the
risk
associated
with
investing
in
those
securities.
Changes
in
valuation
techniques
may
result
in
transfers
in
or
out
of
an
assigned
level
within
the
disclosure
hierarchy.
Valuation
techniques
used
to
value
the
fund’s
investments
are
as
follows:
NOTES
TO
STATEMENT
OF
INVESTMENTS
(Unaudited)
(continued)
BNY
Mellon
ETF
Trust’s
(the
“Trust”) Board
of
Trustees
(the
“Board”)
has
designated
the
Adviser
as
the
fund’s
valuation
designee
to
make
all
fair
value
determinations
with
respect
to
the
fund’s
portfolio
of
investments,
subject
to
the
Board’s
oversight
and
pursuant
to
Rule
2a-5
under
the
Act.
Investments
in
equity
securities,
including
ETFs
(but
not
including
investments
in
other
open-end
registered
investment
companies),
generally
are
valued
at
the
last
sales
price
on
the
day
of
valuation
on
the
securities
exchange
or
national
securities
market
on
which
such
securities
primarily
are
traded.
Securities
listed
on
the
National
Association
of
Securities
Dealers
Automated
Quotation
System
(“NASDAQ”)
for
which
market
quotations
are
available
will
be
valued
at
the
official
closing
price.
If
there
are
no
transactions
in
a
security,
or
no
official
closing
prices
for
a
NASDAQ
market-listed
security
on
that
day,
the
security
will
be
valued
at
the
average
of
the
most
recent
bid
and
asked
prices.
Bid
price
is
used
when
no
asked
price
is
available.
Open
short
positions
for
which
there
is
no
sale
price
on
a
given
day
are
valued
at
the
lowest
asked
price.
Registered
investment
companies
that
are
not
traded
on
an
exchange
are
valued
at
their
net
asset
value.
All
of
the
preceding
securities
are
generally
categorized
within
Level
1
of
the
fair
value
hierarchy.
When
market
quotations
or
official
closing
prices
are
not
readily
available,
or
are
determined
not
to
reflect
fair
value
accurately,
they are
valued
at
fair
value
as
determined
in
good
faith
based
on
procedures
approved
by
the
Board.
Fair
value
of
investments
may
be
determined
by
valuation
designee
using
such
information
as
it
deems
appropriate
under
the
circumstances.
Certain
factors
may
be
considered
when
fair
valuing
investments
such
as:
fundamental
analytical
data,
the
nature
and
duration
of
restrictions
on
disposition,
an
evaluation
of
the
forces
that
influence
the
market
in
which
the
securities
are
purchased
and
sold,
and
public
trading
in
similar
securities
of
the
issuer
or
comparable
issuers.
These
securities
are
either
categorized
within
Level
2
or
3
of
the
fair
value
hierarchy
depending
on
the
relevant
inputs
used.
For
securities
where
observable
inputs
are
limited,
assumptions
about
market
activity
and
risk
are
used
and
are
generally
categorized
within
Level
3
of
the
fair
value
hierarchy.
The
table
below
summarizes
the
inputs
used
as
of November
30,
2023
in
valuing
the
fund’s
investments:
Fair
Value
Measurements
Additional
investment
related
disclosures
are
hereby
incorporated
by
reference
to
the
semi-annual
report
previously
filed
with
the
SEC
on
Form
N-CSR.
At November
30,
2023,
accumulated
net
unrealized
appreciation on
investments
was
$318,793,
consisting
of
gross
appreciation
of
$1,436,998
and
gross
depreciation
of
$1,118,205.
At
November
30,
2023,
the
cost
of
investments
for
federal
income
tax
purposes
was
substantially
the
same
as
the
cost
for
financial
reporting
purposes
(see
the
Statement
of
Investments).
Level
1
-
Unadjusted
Quoted
Prices
Level
2
-
Other
Significant
Observable
Inputs
Level
3
-
Significant
Unobservable
Inputs
Total
Assets
($)
Investments
In
Securities:
†
Common
Stocks
10,228,624
—
—
10,228,624
Investment
Companies
53,346
—
—
53,346
†
See
Statement
of
Investments
for
additional
detailed
categorizations,
if
any.